Literature DB >> 12420793

Affinities of dihydrocodeine and its metabolites to opioid receptors.

Helmut Schmidt1, Stefan v Vormfelde, Klaus Klinder, Ursula Gundert-Remy, Christoph H Gleiter, Gisela Skopp, Rolf Aderjan, Uwe Fuhr.   

Abstract

Dihydrocodeine is metabolized to dihydromorphine, dihydrocodeine-6-O-, dihydromorphine-3-O- and dihydromorphine-6-O-glucuronide, and nordihydrocodeine. The current study was conducted to evaluate the affinities of dihydrocodeine and its metabolites to mu-, delta- and kappa-opioid receptors. Codeine, morphine, d,1-methadone and levomethadone were used as controls. Displacement binding experiments were carried out at the respective opioid receptor types using preparations of guinea pig cerebral cortex and the specific opioid agonists [5H]DAMGO (mu-opioid receptor), [3H]DPDPE (delta-opioid receptor) and [3H]U69,593 (K-opioid receptor) as radioactive ligands at concentrations of 0.5, 1.0 and 1.0 nmol/l, respectively. All substances had their greatest affinity to the mu-opioid receptor. The affinities of dihydromorphine and dihydromorphine-6-O-glucuronide were at least 70 times greater compared with dihydrocodeine (Ki 0.3 micromol/l), whereas the other metabolites yielded lower affinities. For the delta-opioid receptor, the order of affinities was similar with the exception that dihydrocodeine-6-O-glucuronide revealed a doubled affinity in relation to dihydrocodeine (Ki 5.9 micromol/l). In contrast, for the K-opioid receptor, dihydrocodeine-6-O- and dihydromorphine-6-O-glucuronide had clearly lower affinities compared to the respective parent compounds. The affinity of nordihydrocodeine was almost identical to that of dihydrocodeine (Ki 14 micromol/l), whereas dihydromorphine had a 60 times higher affinity. These results suggest that dihydromorphine and its 6-O-glucuronide may provide a relevant contribution to the pharmacological effects of dihydrocodeine. The O-demethylation of dihydrocodeine to dihydromorphine is mediated by the polymorphic cytochrome P-450 enzyme CYP2D6, resulting in different metabolic profiles in extensive and poor metabolizers. About 7% of the caucasian population which are CYP2D6 poor metabolizers thus may experience therapeutic failure after standard doses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12420793     DOI: 10.1034/j.1600-0773.2002.910203.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  10 in total

Review 1.  Role of active metabolites in the use of opioids.

Authors:  Janet K Coller; Lona L Christrup; Andrew A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  2008-10-29       Impact factor: 2.953

Review 2.  Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives.

Authors:  Jörn Lötsch; Carsten Skarke; Jürgen Liefhold; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

3.  In vitro and in vivo pharmacological profile of the 5-benzyl analogue of 14-methoxymetopon, a novel mu opioid analgesic with reduced propensity to alter motor function.

Authors:  Mariana Spetea; Catalina R Bohotin; Muhammad F Asim; Kurt Stübegger; Helmut Schmidhammer
Journal:  Eur J Pharm Sci       Date:  2010-06-18       Impact factor: 4.384

4.  Pharmacokinetic-pharmacodynamic modeling of the miotic effects of dihydrocodeine in humans.

Authors:  Helmut Schmidt; Jörn Lötsch
Journal:  Eur J Clin Pharmacol       Date:  2007-09-05       Impact factor: 2.953

5.  Heteromerization of the μ- and δ-opioid receptors produces ligand-biased antagonism and alters μ-receptor trafficking.

Authors:  Laura Milan-Lobo; Jennifer L Whistler
Journal:  J Pharmacol Exp Ther       Date:  2011-03-21       Impact factor: 4.030

6.  Always consider the possibility of opioid induced respiratory depression in patients presenting with hypercapnic respiratory failure who fail to improve as expected with appropriate therapy.

Authors:  Martin Steynor; Andrew MacDuff
Journal:  Case Rep Crit Care       Date:  2015-03-29

7.  Non-Peptide Opioids Differ in Effects on Mu-Opioid (MOP) and Serotonin 1A (5-HT1A) Receptors Heterodimerization and Cellular Effectors (Ca2+, ERK1/2 and p38) Activation.

Authors:  Vlad Radoi; Gerd Jakobsson; Vinko Palada; Andrej Nikosjkov; Henrik Druid; Lars Terenius; Eva Kosek; Vladana Vukojević
Journal:  Molecules       Date:  2022-04-06       Impact factor: 4.411

8.  Central and peripheral mechanisms of narcotic antitussives: codeine-sensitive and -resistant coughs.

Authors:  Kazuo Takahama; Tetsuya Shirasaki
Journal:  Cough       Date:  2007-07-09

9.  μ Opioid receptor: novel antagonists and structural modeling.

Authors:  Teresa Kaserer; Aquilino Lantero; Helmut Schmidhammer; Mariana Spetea; Daniela Schuster
Journal:  Sci Rep       Date:  2016-02-18       Impact factor: 4.379

Review 10.  Pharmacological Aspects of Over-the-Counter Opioid Drugs Misuse.

Authors:  Łukasz Sobczak; Krzysztof Goryński
Journal:  Molecules       Date:  2020-08-27       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.